breast cancer
Roche under pressure to drop price of Kadcyla
October 27, 2015Manufacturing and Production Cancer Drugs Fund, Kadcyla, Roche, breast cancer
The UK’s largest breast cancer charity has called for drug manufacturer Roche to drop the price of Kadcyla before it …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
Breast cancer treatment market booming
March 19, 2015Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb
The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …
Tamoxifen found to reduce breast cancer rates by 30%
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arimidex, NICE, anastrozole, astrazenea, breast cancer, tamoxifen
A study from Queen Mary University has demonstrated that tamoxifen can reduce breast cancer rates by around 30% over 20 …
Cancer Drugs Fund ‘papering over the cracks of a bigger issue’
October 29, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Kadcyla, NICE, breast cancer, reform
Breakthrough Breast Cancer has raised concerns to the government this week over the ever-increasing price of new oncology medicines. Over …
Pfizer breast cancer pill gets FDA nod
October 14, 2014Research and Development, Sales and Marketing FDA, Femera, LEE011, Pfizer, bemaciclib, breast cancer, palbociclib
Pfizer’s experimental breast cancer drug palbociclib has been accepted and granted a priority review by the US Food and Drug …
Roche should be ‘shamed’ into lowering cancer drug price
September 16, 2014Medical Communications, Sales and Marketing Kadcyla, Margaret Connolly, Roche, Swiss, breast cancer, trastuzumab emtansine
A public petition to force Roche to lower the cost of its costly new breast cancer drug Kadcyla has been …
Genentech to buy Seragon
July 3, 2014Sales and Marketing Genentech, Roche, breast cancer, oncology, serds
Roche subsidiary Genentech is to pay around $1.7 billion for biotech firm Seragon Pharmaceuticals to secure its portfolio of potential …
Pfizer to submit breast cancer drug
May 18, 2014Research and Development, Sales and Marketing Pfizer, breast cancer, femara, palbociclib
Pfizer, currently in the middle of trying to acquire AstraZeneca for $106 billion, says it will soon submit its new …
Herceptin faces UK competition within months
April 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer
Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …
Pfizer breast cancer drug combo aces trial
April 7, 2014Femera, Pfizer, breast cancer, oncology, palbociclib
Servier signs cancer partnership
January 29, 2014Research and Development, Sales and Marketing AbbVie, Servier, breast cancer, curie
Servier has extended by three years its deal with leading research group Curie-Cancer to identify therapeutic targets for treating triple-negative …
Roche’s new Herceptin jab approved by NHS
September 25, 2013Sales and Marketing Herceptin, Kadcyla, Roche, breast cancer
FDA approves first generic Xeloda
September 17, 2013Sales and Marketing FDA, Roche, Teva, Xeolda, breast cancer, colorectal cancer
EU green light for ‘new’ Herceptin
September 3, 2013Sales and Marketing EU, Herceptin, Roche, breast cancer
Roche has ticked another approval off Herceptin’s list with the news that the European Commission is allowing a new form …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
